Treatment with systemic immunostimulatory agents (including, but not limited to, interferon-alpha or interleukin-2 [aldesleukin]) within 6 weeks prior to cycle 1, day 1.Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXMalignancies other than RCC within 5 years prior to Cycle 1, Day 1Xx_NEWLINE_xXPatients may have received one and only one cycle of chemotherapy prior to enrolling on Cancer and Leukemia Group B (CALGB) 30610, which must have included carboplatin or cisplatin and etoposide; if a patient has had one cycle of cisplatin (or carboplatin)/etoposide prior to registration, the patient must have had all of the prior to registration tests prior to starting their first cycle of chemotherapy; additionally, these patients also must have met all of the eligibility criteria prior to receiving the first cycle of chemotherapy; registration to CALGB 30610 must take place within 7-21 days after the start of the non-protocol therapy; failing to do all of the above will make the patient NOT eligible for CALGB 30610Xx_NEWLINE_xXPatients must not have unequivocal disease progression (by RECIST v1.1) during the first cycle; patients must have disease assessed using the same method as baseline within +/- 5 days of the day 56 scheduled assessment (between days 51-55 of cycle 1, or days 1-5 of cycle 2); all disease must be assessed and documented on the follow-up tumor assessment form (RECIST 1.1)Xx_NEWLINE_xXPatients must be registered to step 2: randomization within +/- 5 days of starting cycle 2; patients MUST NOT be registered prior to the day 56 disease assessmentXx_NEWLINE_xXPatients who have not recovered from adverse events to < grade 1 (other than alopecia) due to agents administered more than 3 weeks earlier; however, the following therapies are allowed:\r\n* Hormone replacement therapy or oral contraceptives\r\n* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)\r\n* Palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXTreatment with any other investigational agent within 4 weeks prior to cycle 1, day 1Xx_NEWLINE_xXTreatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXCOHORT 1 PH-NEGATIVE PATIENTS ONLY: Patients must have achieved CR or CRi within 2 cycles of induction/re-induction with blinatumomab\r\n* NOTE: day 1 of post-remission = day 43 of the preceding cycle (+/- 3 days)Xx_NEWLINE_xXPrior treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) is allowed, provided the following is met: minimum of 6 weeks prior to cycle 1, day 1Xx_NEWLINE_xXPhase 1 ONLY: Subject has had any prior anti-cancer therapy other than: Hormonal, non-myelosuppressive, biologic, targeted, or immune therapy (must be completed ? 4 weeks prior to Cycle 1 Day -2). One line of cytotoxic chemotherapy (must be completed ? 4 weeks prior to Cycle 1 Day -2). Adjuvant/neoadjuvant radiotherapy (must be completed ? 12 months prior to Cycle 1 Day -2, with field not involving > 10% of bone marrow reserve).Xx_NEWLINE_xXPhase 2 ONLY: Subject has had any prior chemotherapy, radiotherapy, investigational anti-cancer agents or biologic therapy for the disease under study. Single non-target lesion irradiation with intent of symptom palliation is allowed if ? 4 weeks prior Cycle 1 Day -2.Xx_NEWLINE_xXSubject has a history of seizures within 12 months of Cycle 1 Day-2 or diagnosed neurological condition placing subject at the increased risk of seizures.Xx_NEWLINE_xXSubject has received anti-cancer Chinese medicine or anti-cancer herbal remedies within 14 days prior to Cycle 1 Day-2.Xx_NEWLINE_xXSubject has had major surgery within 6 weeks prior to Cycle 1 Day-2 (subjects must have completely recovered from any previous surgery prior Cycle 1 Day-2).Xx_NEWLINE_xXPeripheral blast count </= 20,000/mm3 at the time of initiation of infusion on Cycle 1 Day 1Xx_NEWLINE_xXPrevious treatment with radiotherapy or immunotherapeutic agents in the 4 weeks prior to study drug administration (Cycle 1 Day 1)Xx_NEWLINE_xXPrevious treatment with any other investigational agent in the 4 weeks prior to study drug administration (Cycle 1 Day 1)Xx_NEWLINE_xXUse of immunosuppressant medications in the 2 weeks prior to study drug administration (Cycle 1 Day 1)Xx_NEWLINE_xXPrior therapy with immune-activating agents within less than 1 cycle length prior to first day of study treatment (e.g. 3 weeks for ipilimumab or pembrolizumab; 2 weeks for nivolumab) (for treatment phase)Xx_NEWLINE_xXAny other systemic or regional anticancer therapy (cytotoxic chemotherapy, embolization) within 3 weeks or 1 cycle length, whichever is shorter, prior to first day of study treatment (for treatment phase)Xx_NEWLINE_xXAntithymocyte globulin or similar anti-T cell antibody therapy ? 4 weeks prior to Cycle 1 Day 1Xx_NEWLINE_xXTreatment with Epstein-Barr virus cytotoxic T lymphocytes or chimeric antigen receptor (CAR) T cells directed against B cells within 8 weeks of Cycle 1 Day 1Xx_NEWLINE_xXReceipt of investigational treatment within 3 weeks of scheduled Cycle 1 Day 1 (C1D1) dosing.Xx_NEWLINE_xXPrior treatment with more than 1 cycle of azacitidine or decitabine.Xx_NEWLINE_xXTreatment with investigational therapy within 14 days prior to Cycle 1, Day 1Xx_NEWLINE_xXTreatment with a monoclonal antibody within 30 days prior to Cycle 1, Day 1Xx_NEWLINE_xXTreatment with any anti-cancer agent 14 days prior to Cycle, Day 1 other than aPD-1 based therapyXx_NEWLINE_xXTreatment with oral or intravenous (IV) antibiotics within 2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXAny Grade >/=3 hemorrhage or bleeding event within 28 days of Day 1 of Cycle 1Xx_NEWLINE_xXThe following laboratory results must be met during screening and also immediately before study drug administration on Cycle 1 Day 1:Xx_NEWLINE_xXPatients with unknown BRAF mutation status may enroll so long as mutation testing is planned to be performed within 30 days of Cycle 1 Day 1 First-line NSCLC (pembrolizumab only)Xx_NEWLINE_xXCompletion of autologous SCT within 100 days prior to Day 1 of Cycle 1Xx_NEWLINE_xXPrior standard or investigational anti-cancer therapy as specified: Radioimmunoconjugate within 12 weeks prior to Day 1 of Cycle 1; Monoclonal antibody or antibody-drug conjugate within 4 weeks prior to Day 1 of Cycle 1; Radiotherapy, chemotherapy, hormonal therapy, or targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXKnown uncontrolled brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least 4 weeks prior to Cycle 1 Day 1). Controlled brain metastases that require continuous high dose corticosteroid use within 4 weeks of Cycle 1 Day 1.Xx_NEWLINE_xXPatients must demonstrate adequate organ function as defined below; all screening labs to be obtained =< 14 days prior to registration; (Note: screening labs will be repeated again on cycle 1 day 1 [C1D1] if they were performed outside of the =< 4 day window)Xx_NEWLINE_xXSubject must have adequate organ function as defined below. The following parameters must be evaluated within 28 days prior to Cycle 0 Day 1 (monotherapy run-in period):Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier; however, the following therapies are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)\r\n* Palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXTreatment with any other investigational agent within 4 weeks prior to cycle 1, day 1Xx_NEWLINE_xXTreatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXMalignancies other than disease under study within 5 years prior to Day 1 of Cycle 1Xx_NEWLINE_xXAverage transfusion requirement of ? 2 units per 28 days of packed RBCs confirmed for a minimum of 112 days immediately preceding Cycle 1 Day 1.Xx_NEWLINE_xXNo consecutive 56 days that was RBC transfusion-free during the 112 days immediately preceding Cycle 1 Day 1.Xx_NEWLINE_xXUse of an ESA within the 4 weeks prior to Cycle 1 Day 1.Xx_NEWLINE_xXHave no symptoms of cranial hypertension or convulsions within 14 days before Cycle 1 Day 1 (anti-epileptic drugs and corticoids are allowed to control any preexisting symptoms)Xx_NEWLINE_xXAllogenic or autologous transplant for hematological malignancy with infusion of stem cells within 90 days before Cycle 1 Day 1, or on active immunosuppressive therapy for graft-versus-host disease (GVHD) or GVHD prophylaxis within 2 weeks of Cycle 1 Day 1.Xx_NEWLINE_xXReceipt of anti-cancer therapy 14 days prior to Cycle 1 Day 1Xx_NEWLINE_xXAlbumin >= 3.0 g/dL within 14 days of starting cycle 1 day 1 treatmentXx_NEWLINE_xXNon-tolerable > Grade 2 neuropathy or evidence of unstable neurological symptoms within 4 weeks of Cycle 1 Day 1.Xx_NEWLINE_xXAutologous or allogenic transplant within the 60 days prior to Cycle 1 Day 1.Xx_NEWLINE_xXHas persistent phosphate level greater than upper limit of normal (ULN) during screening (within 14 days of treatment and prior to Cycle 1 Day 1) and despite medical managementXx_NEWLINE_xXResearch MRI sequences performed at Massachusetts General Hospital Charlestown Navy Yard must be completed =< 7 days of cycle 1 day 1Xx_NEWLINE_xXProgressive disease on bendamustine within 6 months of cycle 1, day 1Xx_NEWLINE_xXPrior radiation therapy or chemotherapy within 2 weeks prior cycle 1, day 1, monoclonal antibody therapy within 4 weeksXx_NEWLINE_xXSignificant neuropathy (grades 3–4, or grade 2 with pain) within 14 days prior cycle 1, day 1Xx_NEWLINE_xXTreatment with systemic steroids for > 4 weeks prior to cycle 1 day 1 of study therapy; prior radiation therapy, with the exception of an abbreviated course (not more than 3 days) if used for superior vena cava (SVC) syndromeXx_NEWLINE_xXThyroid function tests must be consistent with stable thyroid function; patients on a stable dose of thyroid replacement therapy for a suggested minimum of 3 weeks before cycle 1, day 1 are eligibleXx_NEWLINE_xXChemotherapy or targeted therapy within 14 days prior to cycle 1 day 1 of protocol therapyXx_NEWLINE_xXCurrent use or history of receiving a non-approved, investigational treatment within 14 days prior to cycle 1 day 1 of protocol therapyXx_NEWLINE_xXProteinuria < 1 g/dayXx_NEWLINE_xXPrevious radiotherapy within 7 days of Cycle 1 Day 1.Xx_NEWLINE_xXTreatment with any other investigational agent within 3 weeks prior to cycle 1, day 1Xx_NEWLINE_xXTreatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXRadio-immunoconjugate within 12 weeks prior to Day 1 of Cycle 1.Xx_NEWLINE_xXMonoclonal antibody or antibody-drug conjugate (ADC) therapy within 3 weeks prior to Day 1 of Cycle 1.Xx_NEWLINE_xXRadiotherapy, chemotherapy, or targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1.Xx_NEWLINE_xXPrior treatment of PTCL with systemic anti-lymphoma therapies, investigational agents, radiation; exception: may have received 1 cycle of CHOP-like therapy (e.g. CHOP, CHOEP, EPOCH); these participants must initiate day 1 cycle 1 of CHEP-BV no less than 19 days from prior CHOP-like therapyXx_NEWLINE_xXEpisode of significant cardiovascular/cerebrovascular acute disease within 6 months prior to Cycle 1 Day 1Xx_NEWLINE_xXMalignancies other than UC within 5 years prior to Cycle 1, Day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXParticipants who were treated with prior JAK inhibitors for aGvHD; except when the participant achieved complete or partial response and has been off JAK inhibitor treatment for at least 8 weeks prior to Cycle 1 Day 1Xx_NEWLINE_xXFailed prior alloSCT within the past 6 months from Cycle 1 Day 1Xx_NEWLINE_xXUse of other prohibited medications within 7 days prior to cycle 1 day 1 on study (Arms B and C only) (see Appendix 1 for list of prohibited medications)Xx_NEWLINE_xXUse of opioid medications for cancer-related pain, including codeine and dextropropoxyphene, currently or any time within 4 weeks of Day 1, Cycle 1Xx_NEWLINE_xXPrior treatment with bicalutamide (Casodex®) or nilutamide (Nilandron®) within 6 weeks of Cycle 1, Day 1Xx_NEWLINE_xXPrior treatment with 5-alpha reductase inhibitors within 4 weeks of Cycle 1, Day 1Xx_NEWLINE_xXAdministration of an investigational therapeutic agent within 28 days of Cycle 1, Day 1Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXMinor surgical procedure within 15 days of study Cycle 1 Day 1Xx_NEWLINE_xXMalignancies other than colorectal cancer within 5 years prior to Cycle 1 Day 1Xx_NEWLINE_xXPatient must be asymptomatic at time of getting SRS (day 0) on trial; prednisone < 10mg/day for at least 7 days prior to treatment is allowedXx_NEWLINE_xXAt least 1 week since the last systemic therapy regimen prior to Cycle 1 Day 1. Subjects on a stable dose of hydroxyurea for at least 2 weeks prior to Cycle 1 Day 1 may continue on hydroxyurea until Cycle 1 Day 7. Subjects must have recovered to NCI CTCAE v. 4.03 < Grade 2 from all acute toxicities (excluding Grade 2 toxicities that are not considered a safety risk by the Sponsor and Investigator) or toxicity must be deemed irreversible by the Investigator.Xx_NEWLINE_xXOngoing treatment with an anticancer agent for CMML not contemplated in this protocol. Subjects on a stable dose of hydroxyurea for at least 2 weeks prior to Cycle 1 Day 1 may continue on hydroxyurea until Cycle 1 Day 7.Xx_NEWLINE_xXCytotoxic therapy within 21 days prior to cycle 1 day (D) 1Xx_NEWLINE_xXCurrent use of systemic corticosteroids greater than (>) 20 mg prednisone per day (or equivalent), or prior anti-cancer therapy to include: radioimmunoconjugate within 12 weeks; mAb or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXThe tumor site selected for injection cannot have been irradiated within 8 weeks of Cycle 1 Day 1 (C1D1)Xx_NEWLINE_xXSevere infections within 4 weeks prior to Cycle 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXAny systemic anticancer therapy within 3 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXAny radiation treatment to metastatic site within 28 days of Cycle 1, Day 1Xx_NEWLINE_xXHistological confirmation of follicular lymphoma grades I, II diagnosed within 12 months (365 days) prior to registration; NOTE: the day of biopsy should be used as day 1 of diagnosis for this calculationXx_NEWLINE_xXPatients who have received:\r\n* Radiation or chemotherapy =< 4 weeks\r\n* Mitomycin C, nitrosureas, or radio-immunotherapy =< 6 weeks, or\r\n* Immunotherapy or targeted therapy (such as kinase inhibitors) =< 2 weeks prior to cycle 1 day 1; patients who are on ibrutinib at study entry are not required to discontinue ibrutinib for any period of time\r\n* Palliative steroids for disease related symptoms are allowed as long as dose is tapered down to an equivalent of =< 10 mg of oral prednisone daily on cycle 1 day 1Xx_NEWLINE_xXPatients should be asymptomatic for jaundice prior to Day 1.Xx_NEWLINE_xXChemotherapy within 2 weeks of first dose of sEPHB4-HSA (minimum of 6 weeks for nitrosoureas and 8 weeks for bone marrow transplantation) with the following exceptions:\r\n* Hydroxyurea allowed prior to, and up to day +5 of cycle 0 of treatment (max 100 mg/kg/day)\r\n* Corticosteroids allowed until day -3 (max dexamethasone 20mg/day)\r\n* Maintenance chemotherapy for ALL allowed one week prior to start of treatment (e.g., POMP)Xx_NEWLINE_xXAdequate organ function with the following laboratory results during screening (within 21 days) and immediately before study drug administration on Cycle 1 Day 1:Xx_NEWLINE_xXBe willing to provide peripheral blood samples at screening and day 1 of cycle 2 and cycle 3 for correlative studiesXx_NEWLINE_xXPrior treatment with immunotherapy (e.g. ipilimumab, nivolumab, pembrolizumab, atezolizumab) within 6 months of cycle 1 day 1Xx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to first day of studyXx_NEWLINE_xXObtained within 21 days prior to cycle 1, day 1: hemoglobin >= 10 g/dlXx_NEWLINE_xXObtained within 21 days prior to cycle 1, day 1: serum bilirubin =< 1.5 x ULNXx_NEWLINE_xXObtained within 21 days prior to cycle 1, day 1: serum creatinine clearance >= 50ml/minXx_NEWLINE_xXWithin 28 days of cycle 1 day 1: Hemoglobin\t>= 8 g/dLXx_NEWLINE_xXGENERAL: Severe infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.Xx_NEWLINE_xXGENERAL: Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1.Xx_NEWLINE_xXPatients who have received any other investigational agents within the past 28 days prior to cycle 1 day 1Xx_NEWLINE_xXMajor surgery or radiotherapy within 21 days prior to Day 1 of Cycle 1 or anticipation of needing such procedure while receiving study treatmentXx_NEWLINE_xXSevere infections within 4 weeks prior to Day 1 of Cycle 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of clinically relevant infection within 2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXTreatment with oral or IV antibiotics within 2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications within 2 weeks prior to Day 1, Cycle 1 Exclusions Related to Other Medical Conditions or MedicationsXx_NEWLINE_xXAny Grade >=3 hemorrhage or bleeding event within 28 days of Day 1 of Cycle 1Xx_NEWLINE_xXTreatment with any other investigational agent within 4 weeks prior to cycle 1, day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXPrior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been > 7 days since obtaining the serum pregnancy test results.Xx_NEWLINE_xXAny CTCAE Grade 2 or 3 diarrhea (i.e., increase of ? 4 stools per day over baseline), unless attributed to AdV, within 7 days prior to Day 1Xx_NEWLINE_xXNIH Stage 2 or higher acute GVHD of the gut (i.e., diarrhea > 556 mL/m2/day, or severe abdominal pain with or without ileus) within 7 days prior to Day 1Xx_NEWLINE_xXRequirement for mechanical ventilation within 7 days prior to Day 1, or sustained oxygen delivery for > 24 hours within 7 days prior to Day 1, or any oxygen requirement within 48 hours prior to Day 1Xx_NEWLINE_xXReceipt of anti-cancer therapy prior to Cycle 1 Day 1: no chemotherapy, radiation therapy, small molecule tyrosine kinase inhibitor (TKI), or hormonal therapy for the treatment of cancer within 14 days or 5 half-lives (whichever is shorter) of Cycle 1 Day 1. No immune therapy or other biologic therapy (other monoclonal antibodies or antibody-drug conjugates [ADCs]) for the treatment of cancer within 28 days of Cycle 1 Day 1.Xx_NEWLINE_xXAdministration of intravesical BCG within 4 weeks before cycle 1, day 1Xx_NEWLINE_xXBisphosphonate treatment within 7 days prior to initiating study treatment (while on study, bisphosphonates can be administered only once a month, between Days 18 to 21 of the 28-day treatment cycle)Xx_NEWLINE_xXPrior systemic treatment with an azole drug within four weeks of cycle 1 day 1.Xx_NEWLINE_xXCurrent enrollment in an investigational drug or device study or participation in such a study within 30 days of cycle 1 day 1.Xx_NEWLINE_xXPatients who received prior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiotherapy, immunotherapy, biologic therapy, or vaccine therapy) within the last 3 weeks prior to day 1 of cycle 1. Patients are permitted to be on dabrafenib and trametinib at start of therapy without wash-out period prior to day 1 of cycle 1. Dosing will change to protocol determined dose levels on day 1 of cycle 1.Xx_NEWLINE_xXPatients must have no clinical evidence of leptomeningeal or brain metastasis causing spinal cord compression that are symptomatic, untreated, not stable for >= 4 weeks prior to day 1 of cycle 1 (must be documented by imaging), or requiring corticosteroids to manage metastasis-related symptoms. Subjects who have been off of corticosteroids for at least 2 weeks prior to day 1 of cycle 1 or are on a stable dose of =< 10 mg per day of a prednisone equivalent for > 1 month prior to day 1 of cycle 1 can be enrolled. Subjects must also be off of enzyme-inducing anticonvulsants for > 4 weeks prior to day 1 of cycle 1.Xx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to first day of study treatmentXx_NEWLINE_xXPatients whose disease is refractory (defined as evidence of disease progression while on drug or within 3 months of its discontinuation) to more than 2 lines of chemotherapy given for CRPC. Any number of chemotherapies to which the patient’s disease is not refractory are allowed, as long as time on treatment did not exceed 6 months (counted from day 1 of cycle 1 to day 1 of the last cycle of treatment).Xx_NEWLINE_xXBe taking prednisone at a dose of =< 10 mg/day, 7 days prior to starting treatment (cycle 1 day 1[(C1D1])Xx_NEWLINE_xXPotassium >= 3.5 mmol/L (within institutional normal range) within 14 days of cycle 1 day 1Xx_NEWLINE_xXBilirubin =< 1.5 x ULN (unless documented Gilbert's disease) within 14 days of cycle 1 day 1Xx_NEWLINE_xXAny other on-going chemotherapeutic, biologic, radiopharmaceutical, or investigational agent currently or within 28 days of cycle 1 day 1Xx_NEWLINE_xXLymphoma that is not amenable for mandatory pre- and cycle 2 day 15 (C2D15) post-treatment biopsyXx_NEWLINE_xXObtained within 14 days prior to the first study treatment (cycle 1, day 1): lymphocyte count >= 500/uLXx_NEWLINE_xXObtained within 14 days prior to the first study treatment (cycle 1, day 1): hemoglobin >= 9.0 g/dLXx_NEWLINE_xXAny approved anticancer therapy, including chemotherapy and hormonal therapy within 3 weeks prior to initiation of study treatment; however, the following are allowed: a) Hormone-replacement therapy or oral contraceptives b) Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXIf palliative radiotherapy administered, completion of palliative radiation therapy must be >= 2 weeks prior to cycle 1 day 1 of protocol therapyXx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1 day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of active infection within 2 weeks prior to cycle 1 day 1Xx_NEWLINE_xXMinor surgical procedure within 7 calendar days prior to cycle 1 day 1Xx_NEWLINE_xXAdequate haematological and end-organ function, as per the local institutions reference ranges, within 72 hrs prior to day 1 of cycle 1 of treatment defined by the following:Xx_NEWLINE_xXTreatment with chemotherapy or other investigational agents within 28 days (or at least 5 x the half-life of the drug) prior to day 1 cycle 1 of Minnelide™ (6 weeks for nitrosoureas or Mitomycin C).Xx_NEWLINE_xXActive tuberculosis or severe infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXAbility and availability to complete all prescribed biopsies (prior to the first evofosfamide dose and between day 15 of Cycle 2 and day 8 of Cycle 3)Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXFewer than 28 days before Cycle 1 Day 1 since any prior chemotherapy (less than 42 days in the case of mitomycin or a nitrosourea)Xx_NEWLINE_xXFewer than 28 days before Cycle 1 Day 1 since administration of hormonal or biological anti-neoplastic agentsXx_NEWLINE_xXParticipation in another investigational drug trial concurrently or within 30 days of Cycle 1 Day 1, or a vaccine trial within 90 days of Cycle 1 Day 1Xx_NEWLINE_xXPrior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been > 7 days since obtaining the serum pregnancy test results.Xx_NEWLINE_xXChinese participants are excluded from receiving strong and/or moderate CYP3A inhibitors 7 days prior to the initiation of study treatment through the end of intensive PK collection (24 hours post dose on Cycle 1 Day 10).Xx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): Lymphocyte count >= 300/uLXx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXAny approved anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, =< 3 weeks prior to first dose of study drug; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anti-cancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)\r\n* Palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXSevere infections =< 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection =< 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXAny approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)\r\n* Palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXPrior use of any monoclonal antibody within 3 months of the start of Cycle 1Xx_NEWLINE_xXAny investigational therapy within 28 days prior to the start of Cycle 1Xx_NEWLINE_xXOnly participants whose lymphoma is untreated are allowed for the dose-finding portion; for the dose expansion cohort both untreated and participants who have received a maximum of one cycle of combination chemotherapy, including rituximab-containing regimens R-cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone (CHOP) and R-EPOCH, prior are eligible; the start of previous chemotherapy cycle must occur at least 21 days prior and 28 days maximum to beginning treatment under this protocol, and such cycle will count towards the maximum of 6 cycles under this study (i.e. cycle off study will count as cycle 1)Xx_NEWLINE_xXLast cycle of most recent salvage therapy within 8 weeks of enrollmentXx_NEWLINE_xXPrior systemic anti-myeloma therapy within 14 days of Cycle 1 Day 1Xx_NEWLINE_xXImmunosuppressive therapy within 6 weeks of Cycle 1 Day 1Xx_NEWLINE_xXDaily corticosteroid requirement within 2 weeks of Cycle 1 Day 1Xx_NEWLINE_xXAnd have a negative serum pregnancy test ? 10 days of cycle 1, day 1 (C1D1)Xx_NEWLINE_xXLymphocyte count ? 300/uL within 14 days prior to the first study treatment (cycle 1, day 1)Xx_NEWLINE_xXHemoglobin ? 9.0 g/dL within 14 days prior to the first study treatment (cycle 1, day 1)Xx_NEWLINE_xXAny approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXPatients may be on steroids prior to initiation of treatment, provided that, by cycle 1 day 1, steroid use is tapered down to less than or equal to 20 mg/day of prednisoneXx_NEWLINE_xXThe following patients are allowed:\r\n* Patients may have been treated for AML or antecedent hematologic disorder with myeloid growth factors, recombinant erythropoietin, thalidomide, lenalidomide, 5-azacitidine or decitabine\r\n* Any prior chemo therapy must have been completed >= 2 weeks prior to day 1 of study treatment and the participant must have recovered to eligibility levels from prior toxicity\r\n* There is no limit for prior chemo regimens\r\n* Patients may have received hematopoietic stem cell transplantation for AML or other diseases\r\n* Hydroxyurea is allowed prior to day 1 of study treatment for count control and during cycle 1; the use of hydroxyurea is not allowed beyond completion of cycle 1Xx_NEWLINE_xXAdministration of an investigational therapeutic within 30 days of cycle 1, day 1Xx_NEWLINE_xXNeutrophil count >= 1.5 x 10^9/l at cycle 1 day 1 of docetaxel cisplatin and 5-FU (TPF)Xx_NEWLINE_xXHemoglobin >= 10 g/dl at cycle 1 day 1 of TPFXx_NEWLINE_xXWillingness to undergo core biopsy of primary hepatic tumor prior at baseline and again at cycle 2 day 1Xx_NEWLINE_xXWide field radiotherapy within 28 days of cycle 1/day 1 or active side effects of such therapyXx_NEWLINE_xXPatients who have had an active infection requiring systemic therapy =< 7 days prior to day -14 are not eligible UNLESS they are symptom-free and have a negative culture at the time of dosing on day -14Xx_NEWLINE_xXRefractory AML without complete remission (CR) after 2 or more cycles of induction therapy (primary induction failure), or AML relapsed after obtaining a CR and failed one cycle of re-induction therapy; standard dose 10-day decitabine (20 mg/m^2 daily IV x 10 days) or 7-day azacitidine (75-100 mg/m^2 daily SC/IV x 7 days) will be considered as one cycle of induction therapyXx_NEWLINE_xXTreatment within 12 months of cycle 1 day 1 with any Cyp17-lyase inhibitor, any 2nd generation AR antagonist (e.g. enzalutamide), cabazitaxel or carboplatinXx_NEWLINE_xXPatients whose disease is refractory (defined as evidence of disease progression while on drug or within 3 months of its discontinuation) to more than 2 lines of chemotherapy; any number of chemotherapies to which the patient’s disease is not refractory are allowed, as long as time on treatment did not exceed 6 months (counted from day 1 of cycle 1 to day 1 of the last cycle of treatment)Xx_NEWLINE_xXFlutamide (Eulexin) treatment within 4 weeks of cycle 1, day 1 and bicalutamide (Casodex) or nilutamide (Nilandron) within 6 weeks of cycle 1 day 1 (exceptions: if progression is documented prior to this time interval, or if patient is deemed by the treating physician to be highly unlikely to respond to AR inhibitor withdrawal (e.g. if PSA did not decline for 3 months in response to AR inhibitor given as a second line or later intervention, or if patient has symptoms attributable to disease progression) only a 3 day washout prior to cycle 1, day 1 will be required for any of themXx_NEWLINE_xXConsents to whole blood collection prior to initiating therapy, on cycle 2 day 1, and at cystectomy for support of correlative research studiesXx_NEWLINE_xXCurrent or recent (within 10 calendar days prior to cycle 1, day 1) use of dipyridamole, ticlopidine, clopidogrel, or cilostazolXx_NEWLINE_xXTreatment with an investigational therapeutic within 30 days of cycle 1Xx_NEWLINE_xXAvailability of a frozen biopsy core prior to cycle 1, day 1Xx_NEWLINE_xXAdministration of an investigational therapeutic within 30 days of cycle 1, day -2Xx_NEWLINE_xXChemotherapy or hormonal therapy for anti-cancer treatment within 28 days prior to Cycle 1 Day 1.Xx_NEWLINE_xXImmunotherapy or biological therapy (e.g., monoclonal antibodies) within 28 days prior to Cycle 1 Day 1, unless pre-approval is obtained from the Sponsor Medical Monitor.Xx_NEWLINE_xXTreatment with unapproved investigational therapeutic agent within 28 days prior to Cycle 1 Day 1, unless pre-approval is obtained from the Sponsor Medical Monitor.Xx_NEWLINE_xXCytotoxic chemotherapy or non-hormonal targeted therapy within 28 days of Cycle 1 Day 1 is not permitted.Xx_NEWLINE_xXSubjects screened between 1 to 12 weeks after last cycle of chemotherapyXx_NEWLINE_xXPatients must be beyond day 30 and before day 75 after transplantXx_NEWLINE_xXChemotherapy or immunotherapy or any other anticancer therapy =< 3 weeks prior to cycle 1 day 1; hydroxyurea may be continued until 72 hours prior to first dose and at least 24 hours before the baseline bone marrow aspiration is performedXx_NEWLINE_xXHistory of seizures, movement disorders or cerebrovascular accident within the past 1 year prior to cycle 1 day 1Xx_NEWLINE_xXPatients who received prior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last 3 weeks prior to day 1 of cycle 1; patients are permitted to be on dabrafenib and trametinib standard of care at start of therapy without wash-out period prior to day 1 of cycle 1; dosing will change to protocol determined dose levels on day 1 of cycle 1Xx_NEWLINE_xXPatients with known urea cycle disorders (i.e.: ornithine transcarbamylase deficiency)Xx_NEWLINE_xXFixed or decreasing dose of corticosteroids (or no corticosteroids) for at least 1 week prior to cycle 1 day 1Xx_NEWLINE_xXPrior systemic treatment with an azole anti-fungal drug (e.g. fluconazole, itraconazole) within 4 weeks of cycle 1, day 1Xx_NEWLINE_xXAdministration of an investigational therapeutic within 30 days prior to cycle 1, day 1Xx_NEWLINE_xXPatients must be willing to use the Optune device >= 18 hours/day for at least 23 days in a 28-day cycle, and keep head shaved throughout treatmentXx_NEWLINE_xXHistologically confirmed solid tumor malignancy for which platinum-based chemotherapy on a 21-day cycle or 14 day cycle is being recommendedXx_NEWLINE_xXThe patient must be enrolled and have treatment planning between 14-63 days from date of last surgery or last cycle of chemotherapy, and radiation must start within 21-63 days of date of last surgery or last cycle of chemotherapyXx_NEWLINE_xXTreatment with any other investigational agent or participation in another clinical study with therapeutic intent within 30 days prior to Cycle 1 Day 1. For Phase 1b, participants who have received the following prior antitumor therapy: received nitrosoureas and mitomycin C within 6 weeksXx_NEWLINE_xXChemotherapy within 3 weeks of Cycle 1 Day 1Xx_NEWLINE_xXAdequate hematology laboratory values at Cycle 1 Day 1 pre-dosing defined as follows:Xx_NEWLINE_xXAdequate liver function at Cycle 1 Day 1 pre-dosing defined as:Xx_NEWLINE_xXMalignancies other than disease under study within 5 years prior to Day 1 of Cycle 1 except those with a negligible risk of metastasis or deathXx_NEWLINE_xXSpinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated but without evidence that disease has been clinically stable for >/=2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXSevere infection within 4 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXOral or IV antibiotics within 2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXRadiation, chemotherapy, or immunotherapy or any other anticancer therapy =< 2 weeks prior to cycle 1 day 1 (localized radiation to a single site at least 1 week before cycle 1 day 1 is permissible)Xx_NEWLINE_xXTreatment with an investigational therapeutic drug within 30 days of cycle 1Xx_NEWLINE_xXMinimum intervals required to be off treatment prior to Cycle 1 Day 1:Xx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): Lymphocyte count >= 300/uL.Xx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): Hemoglobin >= 9.0 g/dL.Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.Xx_NEWLINE_xXSigns or symptoms of infection as determined by the treating team within 2 weeks prior to cycle 1, day 1.Xx_NEWLINE_xXCancer-related exclusion criteria:\r\n* Patients with known MSI-high status or unknown MSI status are not eligible for study entry\r\n* Patients with BRAF V600E mutations are not eligible for the study\r\n* Surgical procedure (surgical resection, wound revision or any other major surgery) or significant traumatic injury within 60 days prior to enrollment, or anticipation of need for major surgical procedure during the course of the study. Minor surgical procedure within 7 days (including placement of a vascular access device) of study cycle 1 day 1\r\n** Study-related biopsies are NOT considered surgical procedures under the exclusion criteria\r\n* Untreated central nervous system (CNS) metastases. Treatment of brain metastases, either by surgical or radiation techniques, must have been completed at least 4 weeks prior to initiation of study treatment\r\n* Treatment with any investigational agent or approved therapy within 21 days (cycle 1 day 1)\r\n* Malignancies other than CRC within 3 years prior to cycle 1 day 1 with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year overall survival > 90%) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)\r\n* Prior radiation therapy within 14 days prior to study cycle 1 day 1 and/or persistence of radiation-related adverse effects. However, palliative radiation therapy (as long as it does not involve target lesions) is permitted on the study\r\n* Prior allogeneic bone marrow transplantation or solid organ transplant for another malignancy in the past\r\n* Spinal cord compression not definitively treated with surgery and/or radiation\r\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\r\n* Uncontrolled tumor related pain. Patients who require narcotic pain medication during screening should be on a stable dose regimen prior to cycle 1 day 1Xx_NEWLINE_xXExclusion criteria based on organ function or medical history:\r\n* History of clinically significant cardiac or pulmonary dysfunction including the following:\r\n** Inadequately controlled hypertension (that is defined as systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg that is treated or untreated)\r\n** History of myocardial infarction within 6 months prior to first dose of study drug in cycle\r\n** Prior history of hypertensive crisis or hypertensive encephalopathy\r\n** History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, evidence of active pneumonitis on screening chest computed tomography (CT) scan or non-infectious pneuomonitis requiring steroids\r\n* Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months of cycle 1 day 1\r\n* History of stroke or transient ischemic attack within 6 months prior to cycle 1 day 1\r\n* Serious non-healing wound, active ulcer or untreated bone fracture\r\n* History of abdominal fistula or gastrointestinal perforation within 6 months prior to cycle 1 day 1\r\n* History of hemoptysis (?one teaspoon of bright red blood per episode), or any other serious hemorrhage or at risk of bleeding (gastrointestinal history of bleeds, gastrointestinal ulcers, etc.). INR > 1.5 and aPTT > 1.5 x ULN within 7 days prior to cycle 1 day 1. History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding\r\n* Life expectancy of < 12 weeks\r\n* Any previous venous thromboembolism >= grade 3\r\n* Proteinuria at screening as demonstrated by urine dipstick >= 2+ or 24-hour. proteinuria > 1.0 g\r\n* Left ventricular ejection fraction (LVEF) below institutional lower limit of normal\r\n* Uncontrolled serious medical or psychiatric illness\r\n* Pregnant or lactating, or intending to become pregnant during the study. Women who are not post-menopausal (>= 12 continuous months of amenorrhea with no identified cause other than menopause) or surgically sterile must have a negative serum pregnancy test within 14 days prior to cycle 1 day 1Xx_NEWLINE_xXPatients with spinal cord compression or a history of leptomeningeal carcinomatosis. At the time of day 1 of the study, patients with central nervous system metastases must have been treated and must be asymptomatic and meet the following criteria. 1. No concurrent treatment, inclusive of, but not limited to, surgery, radiation, and/or corticosteroids. (Note: patients are allowed on systemic steroids unless these are being administered to manage central nervous system metastases); 2. Neurologic stability (lack of signs or symptoms greater than baseline prior to radiotherapy) until the time of dosing of MEDI0457; 3. For radiation treatment, patients must be: at least 14 days between last day of stereotactic radiosurgery or gamma-knife treatment and day 1 of protocol treatment, at least 28 days between last day of whole brain radiation therapy and day 1 of protocol treatment, and/or at least 14 days since last dose of corticosteroids and day 1 of protocol treatment.Xx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to week 1, day 1Xx_NEWLINE_xXPatients must have cHL that has not been previously treated (patients who have received one dose [day 1 cycle 1] of standard doxorubicin hydrochloride [adriamycin], bleomycin, vinblastine and dacarbazine [ABVD] or doxorubicin hydrochloride, vinblastine, dacarbazine [AVD] may be enrolled as long as they completed all the required standard of care baseline studies before enrollment and initiate study therapy by day 15 cycle 1)Xx_NEWLINE_xXAt cycle 1 day 1 pre-dosing: Creatinine > 2 x ULNXx_NEWLINE_xXLymphocyte count >= 300/uL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)Xx_NEWLINE_xXHemoglobin >= 9.0 g/dL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)Xx_NEWLINE_xXAny approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy > 1 week prior to cycle 1, day 1; herbal therapy intended as anticancer therapy must also be discontinued at least 1 week prior to cycle 1, day 1\r\n* Palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXSurgery or local prostatic intervention (excluding a prostatic biopsy) less than 28 days of Cycle 1 Day 1.Xx_NEWLINE_xXPediatric patients ? 1 day old on Cycle 1 Day 1 (C1D1)Xx_NEWLINE_xXImmunosuppressive therapy within 6 weeks of Cycle 1, Day 1Xx_NEWLINE_xXMaintenance should commence within 60 days of recovery of peripheral blood counts after consolidation cycle 2; patients must begin consolidation cycle 2 within 60 days of recovery to be eligible for further therapyXx_NEWLINE_xXPatients must have resolved any serious infectious complications related to consolidation cycle 2Xx_NEWLINE_xXAny significant medical complications related to consolidation cycle 2 must have resolvedXx_NEWLINE_xXTreatment with any other investigational agent within 4 weeks prior to cycle 1, day 1Xx_NEWLINE_xXTreatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXImmunosuppressive therapy within 6 weeks of Cycle 1, Day 1Xx_NEWLINE_xXSubjects who are willing and able to comply with the protocol and study procedures including willingness to undergo tumor biopsy for tumor cells before therapy at cycle 1, day 1, and day 8 (before cisplatin dose) if this is clinically and safely feasible to do soXx_NEWLINE_xXWillingness to provide the biologic specimens is required by the protocol; this is part of the mandatory correlative research component; these specimens include:\r\n- PHASE I: peripheral blood for plasma pharmacokinetic analysis and peripheral blood mononuclear cell (PBMC) polymer assessment from 0-24 h after drug administration on days 1 and 2 of cycle 1 as well as day 2 of cycle 2; urine for assessment of ABT-888 renal clearance for 24 h after administration of drugs on days 1 and 2 of cycle 1 as well as day 2 of cycle 2; and a pretreatment peripheral blood sample for possible sequencing of the BRCA1, BRCA2 loci as well as possible pharmacogenomic analysisXx_NEWLINE_xXParticipants who have undergone a major surgical procedure or trauma within 4 weeks prior to cycle 1, day 1; all wounds must be fully healed on cycle 1, day 1Xx_NEWLINE_xXPatients who have had chemotherapy or immunotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy within 2 weeks prior to cycle 1 day 1; patients who have had tyrosine kinase inhibitors (such as Braf or MEK inhibitors) within 15 days of cycle 1 day 1Xx_NEWLINE_xXAny approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)Xx_NEWLINE_xXPalliative radiotherapy for bone metastases < 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1 including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXRadiation, chemotherapy, or immunotherapy or any other approved anticancer therapy =< 2 weeks prior to cycle 1 day 1Xx_NEWLINE_xXParticipation in an investigational anti-cancer study within 3 weeks prior to cycle 1 day 1Xx_NEWLINE_xXRadiation, chemotherapy, or immunotherapy or any other anticancer therapy =< 2 weeks prior to cycle 1 day 1 or radio-immunotherapy =< 4 weeks prior to cycle 1 day 1Xx_NEWLINE_xXPatients must have begun cycle 2 (carfilzomib – 27 mg/m^2) and must not have received any dose reduction for toxicity in the last cycle of treatment, immediately preceding progressionXx_NEWLINE_xXParticipants who are untreated or who received a maximum of one (1) cycle of combination chemotherapy, including rituximab-containing regimens, prior are eligible; the start of previous chemotherapy cycle must occur at least 21 days prior to beginning treatment under this protocol, and such cycle will count towards the total maximum of 6 cycles under this studyXx_NEWLINE_xXHas had minor surgery (i.e., simple excision, tooth extraction) <7 days prior to the first dose of study drug (Cycle 1, Day 1).Xx_NEWLINE_xXPatient must be randomized within 12 weeks of the first day of the last cycle of chemotherapyXx_NEWLINE_xXSevere infections within 4 weeks or signs or symptoms of infection within 2 weeks prior to Cycle 1Xx_NEWLINE_xXReceipt of a strong CYP3A4 inducer within 12 days prior to cycle 1 day 1 or a strong CYP3A4 inhibitor within 7 days prior to cycle 1 day 1 (Table 8)Xx_NEWLINE_xXClinically significant bleeding within 14 days of Cycle 1 Day 1 (Treatment Groups B and C only).Xx_NEWLINE_xXSubject has received radiotherapy or radiosurgery within 14 days prior to Cycle 1 Day 1;Xx_NEWLINE_xXSubject use of immunosuppressive medication within 14 days before Cycle 1 Day 1.Xx_NEWLINE_xXPrevious treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid (ie, less than or equal to the equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid treatment must not have been given within 14 days of Cycle 1 Day 1), for Cohort C, the induction and consolidation treatment along with the first Autologous stem cell transplantation (ASCT) are allowed)Xx_NEWLINE_xXClinically significant bleeding within 28 days of Cycle 1 Day 1Xx_NEWLINE_xXHistory of hemoptysis of ? 2.5 mL/1 teaspoon within 6 months of Cycle 1 Day 1Xx_NEWLINE_xXIs unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ?1.3 g per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).Xx_NEWLINE_xXAgree to provide core biopsies at baseline and at Cycle 2 Day 15Xx_NEWLINE_xXAll subjects in Cohort 3 or Phase 2 dose (P2D) must have a lesion accessible for FNA or core or open biopsy on day 8 of the first treatment cycle.Xx_NEWLINE_xXReceipt of any anti-cancer drug/biologic or investigational treatment within 21 days prior to Cycle 1 Day 1 except hormone therapy, which can be given up to 7 days prior to Cycle 1 Day 1; recovery of treatment related toxicity consistent with other eligibility criteriaXx_NEWLINE_xXRadiation therapy within 2 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXMalignancies other than disease under study within 5 years prior to Cycle 1, Day 1Xx_NEWLINE_xXCompletion of autologous SCT within 100 days prior to Day (D) 1 of Cycle (C) 1Xx_NEWLINE_xXAgree to have a medically supervised serum pregnancy test with sensitivity of at least 25 mIU/mL obtained at Screening. A serum pregnancy test is to be performed within 72 hours prior to Day 1 of starting study therapy on Cycle 1 Day -6, and within 72 hours prior to Day 1 of every subsequent cycle, and at the Treatment Discontinuation Visit. The subject may not receive IP until the Investigator has verified that the result of the pregnancy test is negative.Xx_NEWLINE_xXPrior anti-cancer therapy within 2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXPrior radiation therapy within 2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXPrevious treatment with Samarium-153, Strontium-89, Rhenium-186 or Radium-223 within 6 months of starting (i.e., Cycle 1 Day 1) EC1169Xx_NEWLINE_xXA bone marrow biopsy must be performed within four weeks prior to Cycle 1 Day 1 treatment to establish the baseline fibrosis score;Xx_NEWLINE_xXPatients must have been off of chemotherapy for at least 4 weeks prior to day 1 of cycle 1; informed consent can be signed at any time prior to the start of therapyXx_NEWLINE_xXSignificant cardiac event within 12 months before Cycle 1 Day 1.Xx_NEWLINE_xXCurrent or recent (within 10 calendar days prior to cycle 1, day 1) use of dipyramidole, ticlopidine, clopidogrel, or cilostazolXx_NEWLINE_xXTreatment with systemic immunosuppressive medications, including, but not limited to, prednisone, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXFor participants with relapsed or refractory FL: prior allogeneic or autologous stem cell transplantation, anthracycline therapy, treatment with fludarabine or alemtuzumab within 12 months prior to Day 1 of Cycle 1, treatment with a monoclonal antibody, radioimmunoconjugate, or antibody-drug conjugate within 4 weeks prior to Day 1 of Cycle 1, radiotherapy, chemotherapy, hormonal therapy, or targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXParticipant has received anti-myeloma treatment within 2 weeks before Cycle 1 Day 1Xx_NEWLINE_xXPrior use of any monoclonal antibody or antibody-drug conjugate within 4 weeks before Cycle 1, Day 1Xx_NEWLINE_xXRecent major surgery within 4 weeks prior to Cycle 1, Day 1, other than superficial lymph node biopsies for diagnosisXx_NEWLINE_xXParticipants in Phase 1b Stage Only: Vaccination with live vaccines within 6 months before Cycle 1, Day 1Xx_NEWLINE_xXAny radiation treatment to metastatic site within 28 days of Cycle 1, Day 1Xx_NEWLINE_xXDeteriorating neurological symptoms, or need for increasing doses of corticosteroids or new onset of seizures between the screening assessment and cycle 1 day 1Xx_NEWLINE_xXChemotherapy or other investigational therapy within 28 days prior to the start of Cycle 1Xx_NEWLINE_xXAny approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment; however, the following are allowed: i. Hormone-replacement therapy or oral contraceptives ii. Herbal therapy > 1 week prior to Cycle 1, Day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to Cycle 1, Day 1)Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXAdministration of intravesical bacillus Calmette-Guerin (BCG) within 4 weeks before cycle 1, day 1Xx_NEWLINE_xXAny approved anti-cancer therapy within 3 weeks prior to enrollment with the following exceptions: \r\n* Palliative radiotherapy for bone metastases must be completed > 7 days prior to baseline imaging and > 21 days prior to cycle 1 day 1 of treatment\r\n* Hormone replacement therapy or oral contraceptives are permitted \r\n* Administration of intravesical bacillus Calmette-Guerin (BCG) > 4 weeks before cycle 1, day 1 is allowedXx_NEWLINE_xXAny approved anti-cancer therapy within 3 weeks prior to enrollment o Administration of intravesical bacillus Calmette-Guerin (BCG) > 4 weeks before cycle 1, day 1 is allowedXx_NEWLINE_xXSubject consents to hospitalization for first (Cycle 1 Day 1) dose of CC-90002 and for 72 hours after.Xx_NEWLINE_xXTreatment with any other investigational agent within 4 weeks prior to cycle 1, day 1Xx_NEWLINE_xXTreatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): Lymphocyte count >= 500/uLXx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXAny approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives \r\n* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1 including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXUse more than 3 g/day of acetaminophenXx_NEWLINE_xXRadiation, chemotherapy, or immunotherapy or any other anticancer therapy =< 3 weeks prior to cycle 1 day 1; treatment with mitomycin C or radio-immunotherapy must be completed within 6 weeks prior to cycle 1 day 1Xx_NEWLINE_xXHistory of seizures, movement disorders or cerebrovascular accident within the past 5 years prior to cycle 1 day 1Xx_NEWLINE_xXParticipation in an investigational anti-cancer study within 3 weeks prior to cycle 1 day 1Xx_NEWLINE_xXAdministration of an investigational agent within 4 weeks of Treatment Cycle 1, Day 1Xx_NEWLINE_xXChemotherapy, or immunotherapy for the treatment of prostate cancer within 4 weeks of Treatment Cycle 1, Day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXHave postmenopausal status due to either surgical/natural menopause or ovarian suppression (initiated at least 28 days prior to Day 1 of Cycle 1) with a gonadotropin-releasing hormone (GnRH) agonist such as goserelinXx_NEWLINE_xXSerum direct bilirubin < 2 mg/dL (34 Omol/L) within 30 days prior to cycle 1 day 1Xx_NEWLINE_xXChemotherapy (approved or investigational) within 3 weeks prior to the first day of treatment or antibody therapy within 6 weeks prior to the first day of treatmentXx_NEWLINE_xXReceived crizotinib within 3 days of the first dose of brigatinib (Day 1, Cycle 1).Xx_NEWLINE_xXReceived monoclonal antibodies or had major surgery within 30 days of the first dose of brigatinib (Day 1, Cycle 1).Xx_NEWLINE_xXHistory of seizures, movement disorders or cerebrovascular accident within the past 3 years prior to cycle 1 day 1Xx_NEWLINE_xXThromboembolism within 6 months of cycle 1, day 1Xx_NEWLINE_xXSurgery or local prostatic intervention within 4 weeks of the first dose; in addition, any clinically relevant issues from the surgery must have resolved prior to cycle 1, day 1Xx_NEWLINE_xXStrontium-89, samarium-153, or radium-223 therapy within 4 weeks of cycle 1, day 1Xx_NEWLINE_xXRadiotherapy, chemotherapy or immunotherapy within 4 weeks, or palliative radiation to bone metastases within 14 days of administration of cycle 1, day 1Xx_NEWLINE_xXCurrent enrollment in an investigational drug or device study or participation in such a study within 4 weeks of cycle 1, day 1Xx_NEWLINE_xXNo treatment with an investigational product or device within 21 days of cycle 1 day 1Xx_NEWLINE_xXNo treatment with cytotoxic therapy or monoclonal antibodies within 21 days prior to cycle 1 day 1Xx_NEWLINE_xXNo treatment with a steroid intended to treat myeloma within 14 days prior to cycle 1 day 1Xx_NEWLINE_xXNo significant neuropathy (grades 3-4, or grade 2 with pain) within 14 days prior to cycle 1 day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to Cycle 1 Day 1Xx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to Cycle 1 Day 1Xx_NEWLINE_xXReceived therapeutic oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1Xx_NEWLINE_xXRadiation therapy for treatment of the primary tumor within 6 weeks of cycle 1, day 1Xx_NEWLINE_xXRadiation or radionuclide therapy for treatment of metastatic CRPC tumor within 2 or 6 weeks, respectively, of cycle 1, day 1Xx_NEWLINE_xXPrior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4 weeks of cycle 1, day 1Xx_NEWLINE_xXPrior flutamide (Eulexin) treatment within 4 weeks of cycle 1, day 1 (patients whose PSA did not decline for three or more months in response to antiandrogen given as a second line or later intervention will require only a two week washout prior to cycle 1, day 1)Xx_NEWLINE_xXBicalutamide (Casodex), nilutamide (Nilandron) within 6 weeks of cycle 1 day 1 (patients whose PSA did not decline for three or more months in response to antiandrogen given as a second line or later intervention will require only a two week washout prior to cycle 1, day 1)Xx_NEWLINE_xXAdministration of an investigational therapeutic within 30 days of cycle 1, day 1Xx_NEWLINE_xXSubjects must have platelet count greater than 25,000 per microliter at baseline and at the start of study (day 1, cycle 1) visitXx_NEWLINE_xXObtained within 14 days prior to the first study treatment (cycle 1, day 1); lymphocyte count ? 300/uLXx_NEWLINE_xXObtained within 14 days prior to the first study treatment (cycle 1, day 1); hemoglobin ? 9.0 g/dLXx_NEWLINE_xXAny approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy ? 3 weeks prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)\r\n* Palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXPrior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4 weeks of cycle 1, day 1Xx_NEWLINE_xXAdministration of an investigational therapeutic within 30 days of cycle 1, day 1Xx_NEWLINE_xXClinical significant gastrointestinal bleeding in the 6 months prior to Cycle 1 Day 1 (C1D1) first doseXx_NEWLINE_xXAdministration of an investigational therapeutic drug within 30 Days of Cycle 1 Day 1Xx_NEWLINE_xXExperimental medications within the last 4 weeks prior to day 1Xx_NEWLINE_xXUse of any prohibited concomitant medications within 30 days prior to cycle 1, day 1Xx_NEWLINE_xXAdministration of an investigational therapeutic within 30 days of cycle 1, day 1Xx_NEWLINE_xXRadiotherapy or systemic therapy within 2 weeks of Cycle 1 Day 1 (C1D1)Xx_NEWLINE_xXNeutrophils > 1,000/uL prior to day 0Xx_NEWLINE_xXReceived anticancer agent(s) or an investigational agent within 21 days prior to C1D1, or radiotherapy within 28 days prior Cycle 1 Day 1Xx_NEWLINE_xXTreatment with an investigational product or device within 21 days of cycle 1 day 1Xx_NEWLINE_xXCytotoxic therapy or monoclonal antibodies within 21 days prior to cycle 1 day 1Xx_NEWLINE_xXRegular treatment with corticosteroids during the 4 weeks prior to the start of Cycle 1Xx_NEWLINE_xXPatients had at least one prior regimen consisting of at least 1 cycleXx_NEWLINE_xXPatients who have had chemotherapy within 3 weeks or radiotherapy or targeted therapy 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier; however, the following therapies are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)\r\n* Palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXTreatment with any other investigational agent within 4 weeks prior to cycle 1, day 1Xx_NEWLINE_xXTreatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXPeripheral white blood cell (WBC) count 30,000/µL For cyto-reduction, hydroxyurea is allowed during screening and up to Cycle 1, Days 1-14, to reduce WBC count to < 30,000 µL prior to Day 1. After Cycle 1, Day 14, hydroxyurea is prohibited.Xx_NEWLINE_xXPlatelet count > 600 × 10^9/L after 3 months of at least 2 g/day of hydroxyurea (2.5 g/day in subjects with a body weight over 80 kg) OR at the subject's maximally tolerated dose if that dose is < 2 g/day.Xx_NEWLINE_xXHerbal therapy (including herbal therapy intended as anticancer therapy) < 1 week prior to cycle 1, day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXChemotherapy or other investigational therapy within 28 days prior to the start of Cycle 1Xx_NEWLINE_xXPrior treatment with bendamustine (within 2 years of the start of Cycle 1)Xx_NEWLINE_xXIn calculating days of tests and measurements, the day a test or measurement is done is considered day 0; therefore, if a test is done on a Monday, the Monday four weeks later would be considered day 28; this allows for efficient patient scheduling without exceeding the guidelines; if day 28 or 42 falls on a weekend or holiday, the limit may be extended to the next working dayXx_NEWLINE_xXAt least 4 weeks must elapse between the completion of the last chemotherapy, immunotherapy, glucocorticoid therapy, radiotherapy or experimental therapy and administration of the first vaccine; completion is defined as last day of any treatment/therapy, not last day of last cycleXx_NEWLINE_xXUse of systemic corticosteroids ? 2 weeks before Cycle 1 Day 1.Xx_NEWLINE_xXActive, clinically serious infections of NCI CTCAE v4.0 Grade 2 or higher within 4 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti tumor necrosis factor [TNF] agents) within 2 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXReceived the last dose of previous treatment / therapy before Day 1 of cycle 1:Xx_NEWLINE_xXHave initiated treatment with bisphosphonates or approved receptor activator of nuclear factor kappa-B ligand (RANK-L) targeted agents (e.g. denosumab) ? 28 days prior to Day 1 of Cycle 1.Xx_NEWLINE_xXPalliative radiation therapy within 2 weeks of Day 1, or within 4 weeks of Day 1 if a radionuclide was utilized.Xx_NEWLINE_xXInitial diagnosis of advanced stage disease must have occurred ? 6 weeks prior to starting Cycle 1 Day 1. NOTE: The clock for this time interval starts with the date of last evaluation confirming advanced disease (either biopsy or imaging results).Xx_NEWLINE_xXSubject has adequate biological parameters as demonstrated by the following blood counts at screening (obtained ? 14 days prior to starting Cycle 1 Day 1):Xx_NEWLINE_xXSubject has the following blood chemistry levels at screening (obtained ? 14 days prior to starting Cycle 1 Day 1):Xx_NEWLINE_xXSubject has no clinically significant abnormalities in urinalysis results (obtained ? 14 days prior to starting Cycle 1 Day 1).Xx_NEWLINE_xXSignificant or symptomatic amounts of ascites should be drained prior to Cycle 1 DayXx_NEWLINE_xXPain symptoms should be stable and should not require modifications in analgesic management prior to Cycle 1 Day 1.Xx_NEWLINE_xXRadiation, chemotherapy, or immunotherapy or any other anticancer therapy ? 2 weeks prior to Cycle 1 Day 1, except ibrutinib which may be continued until one day prior to initiation of selinexor; radio-immunotherapy 4 weeks prior to Cycle 1 Day 1. Patients must have recovered to Grade ? 1 from clinically significant adverse effects.Xx_NEWLINE_xXAt least 21 days must have elapsed prior to Day 1 Cycle 1, since any radiotherapy, immunotherapy or following major surgery; any surgical incision should be completely healed. At least 14 days must have elapsed prior to Day 1 Cycle 1 since \limited palliative radiotherapy\, defined as a course of therapy encompassing <25% total bone marrow volume and not exceeding 30 GY.Xx_NEWLINE_xXPatients who have had any chemotherapy regimens, biologic, or targeted therapies within the 2 weeks prior to Cycle 1 Day 1Xx_NEWLINE_xXCompleted at least one cycle of the treatmentXx_NEWLINE_xXHydroxyurea to control peripheral blood blast count must be discontinued within 24 hours prior to the initiation of treatment; hydroxyurea can also be given through the first cycle of treatment, but should not be initiated earlier than day 5Xx_NEWLINE_xXSubjects with an active infection or with a fever >/+ 38.5 degrees C within 3 days of the first scheduled day of dosing for Cycle 1Xx_NEWLINE_xXAny malignancy within 5 years prior to Cycle 1, Day 1Xx_NEWLINE_xXAny approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 5 years prior to initiation of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)Xx_NEWLINE_xXSevere infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to cycle 1, day 1Xx_NEWLINE_xXIs, within 2 weeks prior to Day 1, nursing.Xx_NEWLINE_xXCurrent use of systemic corticosteroids greater than (>) 20 milligrams (mg) prednisone per day (or equivalent); or prior anti-cancer therapy to include: radioimmunoconjugate within 12 weeks; mAb or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXPrior abiraterone treatment completed at least 4 weeks prior to cycle 1 day 1. Participants must have failed prior abiraterone treatment.Xx_NEWLINE_xXPrior systemic treatment with an azole drug (fluconazole, itraconazole) within 4 weeks of cycle 1 day 1.Xx_NEWLINE_xXHave initiated treatment with bisphosphonates or approved receptor activator of nuclear factor kappa-B ligand (RANK-L) targeted agents (e.g. denosumab) ?28 days prior to day 1 of cycle 1.Xx_NEWLINE_xXAnti-cancer therapy within the period immediately before Cycle 1 Day 1Xx_NEWLINE_xXAny concurrent chemotherapy, biologic, hormonal, radiation, or investigative therapy for cancer treatment within 21 days prior prior or within 6 weeks prior to Cycle 1/Visit Day 1 for nitrosoureas or mitomycin C;Xx_NEWLINE_xXExperimental therapy within 4 weeks prior to first dose of study-drug treatment in Cycle 1Xx_NEWLINE_xXPrior therapy before Day 1 of Cycle 1 for the treatment of Stage IV pancreatic cancerXx_NEWLINE_xXPrior therapy before Day 1 of Cycle 1 for the treatment of Stage IV pancreatic cancerXx_NEWLINE_xXMalignancies other than UC within 5 years prior to Cycle 1, Day 1Xx_NEWLINE_xXPatients that take acetaminophen (paracetamol) chronically, i.e. more than 1 g/day for more than 3 out of 7 days, or more than 2 g/day for more than 1 day out of 7 daysXx_NEWLINE_xXRadiation, chemotherapy, or immunotherapy or any other anticancer therapy =< 2 weeks prior to cycle 1 day 1; any clinical trial therapy (including investigational anti-cancer study) =< 3 weeks prior to cycle 1 day 1Xx_NEWLINE_xXHistory of seizures, movement disorders or cerebrovascular accident within the past 5 years prior to cycle 1 day 1Xx_NEWLINE_xXHistory of seizures, movement disorders or cerebrovascular accident within the past 3 years prior to cycle 1 day 1Xx_NEWLINE_xXHistory of intra-abdominal inflammatory process within 6 months prior to Day 1 of Cycle 1 including but not limited to peptic ulcer disease, diverticulitis, or colitisXx_NEWLINE_xXHemoglobin >= 8.0 g/dL obtained at baseline (day 1 of cycle 1, before study drug administration)Xx_NEWLINE_xXSystemic cytotoxic therapies or radiotherapy ?14 days prior to day 1 cycle 1Xx_NEWLINE_xXFor two weeks prior to day 1 cycle 1, administration of specified cytochrome P450 3A (CYP3A) inducersXx_NEWLINE_xXPatients who have been treated with an investigational agent <21 days prior to day 1 of cycle 1Xx_NEWLINE_xXWhole brain or focal radiation therapy within 14 days prior to Cycle 1 Day 1 (C1D1) for Phase 1b or prior to randomization for Phase 2Xx_NEWLINE_xXAll pre-study labs required for determination of eligibility are to be completed within 30 days prior to day -2 (or the next business day if falls on a weekend or holiday)Xx_NEWLINE_xXX-rays and/or scans to assess all disease sites are to be completed within 30 days prior to day -2 (or the next business day if falls on a weekend or holiday)Xx_NEWLINE_xXAdministration of an investigational therapeutic within 30 days of cycle 1, day 1Xx_NEWLINE_xXClinically significant gastrointestinal (GI) bleeding within 6 months prior to Cycle 1, Day 1Xx_NEWLINE_xXAt least 21 days must have elapsed prior to day 1 cycle 1, from chemotherapy, radiotherapy, immunotherapy or following major surgery and any surgical incision should be completely healed. At least 14 days must have elapsed prior to Day 1 Cycle 1 for \limited palliative radiotherapy\, defined as a course of therapy encompassing < 25% total bone marrow volume and not exceeding 30 Gy.Xx_NEWLINE_xXAdequate bone marrow, liver, and renal function within the 14 days prior to Day 1 of Cycle 1 of study drug up until pre-dose of Cycle 1Xx_NEWLINE_xXParticipants with persistent phosphate greater than upper limit of normal during screening (within 14 days prior to Day 1 of Cycle 1 up until pre-dose of Cycle 1) and despite medical management of phosphate levelsXx_NEWLINE_xXVomited in the 24 hours prior study drug administration (Cycle 1)Xx_NEWLINE_xXSmall molecular cell cycle inhibitors >= 2 weeks from registrationXx_NEWLINE_xXPrior use of any MAb, radioimmunoconjugate, or antibody-drug conjugate (ADC) within 4 weeks or 5 half-lives before Cycle 1 Day 1Xx_NEWLINE_xXTreatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to Cycle 1 Day 1Xx_NEWLINE_xXSubjects are allowed to have received radiotherapy before enrollment if radiation was given to alleviate pain and/or neurologic compromise as long as there remains areas of measurable disease present; further, at the investigator’s discretion and for patients who are unstable, one cycle of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) during the phase I portion of trial and one cycle of an anthracycline based chemotherapy in the phase II portion of the trial is allowed prior to enrollment but no more than one cycle; for purposes of this trial, prednisone or other corticosteroids used for non-lymphomatous conditions will be allowed; in addition, a prior/recent short course (=< 2 weeks) of steroids for symptom relief of lymphoma-related symptoms will be allowedXx_NEWLINE_xXAntithymocyte globulin or similar anti-T cell antibody therapy ? 4 weeks prior to Cycle 1 Day 1Xx_NEWLINE_xXTreatment with Epstein-Barr virus cytotoxic T lymphocytes, chimeric antigen receptor (CAR)-T cells directed against B cells, or unselected donor lymphocyte infusion (DLI) within 8 weeks of Cycle 1 Day 1Xx_NEWLINE_xXAny history of an immune-related Grade 3 adverse event attributed to prior CIT (other than hypothyroidism managed with replacement therapy) that resulted in permanent discontinuation of the prior immunotherapeutic agent and/or occurred less than or equal to (<=) 6 months prior to Cycle 1 Day 1Xx_NEWLINE_xXMalignancies other than disease under study within 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or deathXx_NEWLINE_xXTreatment with systemic immunosuppressive medications within 2 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXSevere infections within 4 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXNeutrophil count < 1.5 × 10^9/liter (L) prior to dosing on Cycle 1 Day 1Xx_NEWLINE_xXRadiation, chemotherapy, or immunotherapy or any other anticancer therapy ?3 weeks prior to cycle 1 day 1 and mitomycin C and radioimmunotherapy 6 weeks prior to cycle 1 day 1;Xx_NEWLINE_xXRadiation, chemotherapy, or immunotherapy or any other anticancer therapy ?2 weeks prior to cycle 1 day 1 and mitomycin C and radioimmunotherapy 6 weeks prior to cycle 1 day 1.Xx_NEWLINE_xXPrior anti-cancer therapy or radiotherapy within 2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xX?2 weeks for cytotoxic therapy (except hydroxyurea, which is permitted at doses of ?5g/day during the first 2 weeks of Cycle 1) prior to C1D1.Xx_NEWLINE_xXThe participant is unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose less than or equal to 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).Xx_NEWLINE_xXGlaucoma diagnosed within one month prior to study Day 1.Xx_NEWLINE_xXUse of opiate analgesics for cancer-related pain, including codeine and dextropropoxyphene, currently or anytime within 4 weeks of Cycle 1 Day 1Xx_NEWLINE_xXTreatment with demethylating agents within 21 days prior to Cycle 1, Day 1Xx_NEWLINE_xXTreatment with any anticancer therapy (standard or investigational) within 21 days prior to Cycle 1, Day 1 or ongoing adverse events from previous treatmentXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXTreatment with systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (TNF)) within 2 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXReceived therapeutic oral or IV antibiotics within 4 weeks prior to Cycle 1, Day 1 (except for tumor fever)Xx_NEWLINE_xXNot received carfilzomib within 6 months (183 days) of Cycle 1 Day 1 (C1D1), andXx_NEWLINE_xXRadiation, chemotherapy, or immunotherapy or any other anticancer therapy =< 2 weeks prior to cycle 1 day 1Xx_NEWLINE_xXParticipation in an investigational anti-cancer study =< 3 weeks prior to cycle day 1Xx_NEWLINE_xXPatient received radiation therapy or major surgery within one month of Cycle 1 Day 1Xx_NEWLINE_xXCYCLE II PORTION ONLY: Only participants with a nausea score >= 3 at least once on the diary assessment from cycle 1 can be randomized for cycle 2Xx_NEWLINE_xXCYCLE II PORTION ONLY: Participants must be scheduled to receive the same chemotherapy regimen as received at cycle 1Xx_NEWLINE_xXCYCLE II PORTION ONLY: Must not have received Akynzeo at cycle 1Xx_NEWLINE_xXCYCLE II PORTION ONLY: Must still meet all the exclusion criteria for cycle 1Xx_NEWLINE_xXPrior to Administration of Ibrutinib (Day 60 to Day 90 post HCT)Xx_NEWLINE_xXPRIOR TO ADMINISTRATION OF IBRUTINIB (DAY 60-DAY 90 POST SCT)Xx_NEWLINE_xX7th or later cycle of intravenous carboplatin or oxaliplatin infusion planned or 4 months after the first cycle of agent (whichever is of longer duration) =< 30 days after registrationXx_NEWLINE_xXPatient is scheduled to receive adjuvant temozolomide at either 150 mg/m^2 or 200 mg/m^2 PO x 5 days out of a 28 day cycle +/- bevacizumabXx_NEWLINE_xXStudy participation will occur during the first cycle of 5 day temozolomide courseXx_NEWLINE_xXSigns or symptoms of significant infection within 2 weeks prior to Day 1Xx_NEWLINE_xXReceived oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1Xx_NEWLINE_xXTreatment with systemic corticosteroids or other immunosuppressive medications within 2 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXHistory of intestinal obstruction and/or clinical signs or symptoms of GI obstruction within 6 months prior to Day 1 of Cycle 1Xx_NEWLINE_xXHistory of intra-abdominal inflammatory process within 6 months prior to Day 1 of Cycle 1Xx_NEWLINE_xXTreatment with any HCV anti-viral therapy within 4 weeks prior to Cycle 1 Day 1Xx_NEWLINE_xXInclusion Criteria (All):\n\n          -  Written informed consent must\n\n          -  Patient has histologically and/or cytologically confirmed malignancies:\n\n        Phase I:\n\n        • Patients with advanced or metastatic solid tumors who have failed at least one prior line\n        of systemic antineoplastic therapy in the advanced setting without a standard of care\n        treatment option available;\n\n        Phase II:\n\n          -  Advanced or metastatic pancreatic adenocarcinoma who have failed at least one prior\n             systemic antineoplastic therapies in the advanced setting\n\n          -  Advanced or metastatic KRAS-mutant CRC who have failed at least two prior systemic\n             antineoplastic therapies in the advanced setting without a standard of care treatment\n             option available. Testing for KRAS mutation in patients with CRC using locally\n             approved diagnostic kit will be used for eligibility.\n\n          -  Phase II only: patient must have measurable disease\n\n          -  Patient has an ECOG performance status 0 or 1.\n\n          -  Patient has adequate bone marrow and organ function\n\n          -  Patient must have specified laboratory values within normal limits or corrected to\n             within normal limits with supplements before the first dose of study medication on\n             Cycle 1 Day 1:\n\n          -  Standard 12-lead ECG values defined\n\n        Exclusion Criteria:\n\n        Phase II only:\n\n        • Patient has received prior treatment with a MEK inhibitor or a CDK4/6 inhibitor.\n\n        Phase I and Phase II:\n\n          -  Patient with a known hypersensitivity to the study drugs or any of the excipients of\n             ribociclib or trametinib.\n\n          -  Patient is concurrently using other anti-cancer therapy.\n\n          -  Patient has received radiotherapy ? 4 weeks or limited field radiation for palliation\n             ? 2 weeks prior to Cycle 1 Day 1\n\n          -  Patient has received local therapy to liver ? 3 months of C1D1\n\n          -  History of liver disease as follow:\n\n          -  Cirrhosis\n\n          -  Autoimmune hepatitis\n\n          -  Portal hypertension\n\n          -  Drug induced liver steatosis\n\n          -  Prior systemic anti-cancer treatment within 28 days prior to Cycle 1 Day 1\n\n          -  Prior therapy with anthracyclines at cumulative doses of 450 mg/ m2 or more for\n             doxorubicin or 900 mg/m2 or more for epirubicin.\n\n          -  Patient is currently receiving warfarin or other coumadin derived anti-coagulant\n\n          -  Patient has a history of deep venin thrombosis or pulmonary embolism within 6 months\n             of screening.\n\n          -  Patient has a concurrent malignancy or malignancy within 3 years prior to Cycle 1 Day\n             1, with the exception of adequately treated basal or squamous cell carcinoma or\n             curatively resected cervical cancer.\n\n          -  Patients with central nervous system (CNS) involvement\n\n          -  Patient has impairment of GI function or GI disease that may significantly alter the\n             absorption of the study drugs\n\n          -  History of interstitial lung disease or pneumonitis.\n\n          -  Clinically significant, uncontrolled heart disease and/or cardiac repolarization\n             abnormality\n\n          -  Patient is currently receiving any strong inducers or inhibitors of CYP3A4/5 and/or\n             Substances that have a narrow therapeutic window and are predominantly metabolized\n             through CYP3A4/5 and cannot be discontinued 7 days prior to Cycle 1 Day 1:\n\n          -  Patient is currently receiving or has received systemic corticosteroids ? 2 weeks\n             prior to starting study drug, or who have not fully recovered from side effects of\n             such treatment.\n\n          -  History of retinal vein occlusion (RVO)\n\n        Other protocol-defined inclusion/exclusion criteria may apply.Xx_NEWLINE_xXPrior anti-cancer therapy within 4 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXDescribe fatigue as being present every day for most of day for a minimum of 2 weeksXx_NEWLINE_xXDescribe fatigue as being present every day for most of the day for a minimum of 2 weeksXx_NEWLINE_xXKnown urea cycle disorders based on historyXx_NEWLINE_xXAt least one muscle spasm per day at time of screeningXx_NEWLINE_xXIf currently menstruating, must know the date of the first day of their latest menstrual cycleXx_NEWLINE_xXInclusion Criteria:\n\n        Cycle 1:\n\n        The following inclusion criteria must be checked prior to inclusion at Cycle 1:\n\n          1. Patient read, understood and signed the written informed consent before any study\n             related activity, agreeing to participate in the study and to comply with study\n             requirements.\n\n          2. Female patient of at least 8 years of age.\n\n          3. Histologically or cytologically confirmed breast cancer, including recurrent or\n             metastatic.\n\n          4. Naïve to moderately or highly emetogenic antineoplastic agents.\n\n          5. Scheduled to receive at least 4 consecutive cycles of an AC combination regimen.\n\n             Notes:\n\n               1. additional not emetogenic, minimally or low emetogenic antineoplastic agents are\n                  permitted at any time after start of AC combination on Day 1.\n\n               2. additional highly or moderately emetogenic antineoplastic agents are only allowed\n                  on Day 1 after the start of AC combination, provided their administration is\n                  completed within 6 hours from the start of the AC combination administration.\n\n          6. ECOG Performance Status of 0 or 1.\n\n          7. Patient shall be: a) of non-childbearing potential or b) of childbearing potential\n             using reliable contraceptive measures and having a negative urine pregnancy test\n             within 24 hours prior to dose of investigational product.\n\n             Notes:\n\n               1. Female patients of non-childberaring potential are defined as being in\n                  post-menopausal state since at least 1 year; or having documented surgical\n                  sterilization or hysterectomy at least 3 months before study participation.\n\n               2. Reliable contraceptive measures include implants, injectables, combined oral\n                  contraceptives, intrauterine devices, vasectomized partner or complete (long\n                  term) sexual abstinence;\n\n          8. Hematologic and metabolic status adequate for receiving a cycle of AC chemotherapy\n             based on investigator's assessment.\n\n          9. If the patient has a known hepatic or renal impairment, she may be enrolled in the\n             study at the discretion of the Investigator.\n\n         10. Able to read, understand, follow the study procedure and complete the patient diary.\n\n        All inclusion criteria will be checked at screening visit (Visit 1 of Cycle 1); inclusion\n        criteria 7 will be re-checked at Day 1 (Visit 2).\n\n        Cycles 2 to 4:\n\n        The following inclusion criteria must be checked prior to inclusion at each repeated cycle:\n\n          1. Participation in the study during the next cycle of chemotherapy is considered\n             appropriate by the Investigator and does not pose unwarranted risk to the patient.\n\n          2. Scheduled to receive an AC chemotherapy regimen or AC chemotherapy together with other\n             chemotherapies as defined in Inclusion criterion #5 for Cycle 1.\n\n          3. Patient shall be: a) of non-childbearing potential or b) of childbearing potential\n             using reliable contraceptive measures and having a negative urine pregnancy test\n             within 24 hours prior to dosing of investigational product.\n\n          4. Adequate hematologic and metabolic status for receiving a cycle of AC chemotherapy\n             according to the Investigator's opinion.\n\n        All inclusion criteria will be checked at screening visit (Visit 1); inclusion criterion #3\n        will be re-checked at Day 1 (Visit 2).\n\n        Exclusion Criteria:\n\n        Cycle 1:\n\n        The following exclusion criteria must be checked prior to inclusion at Cycle 1:\n\n          1. Lactating patient.\n\n          2. Current use of illicit drugs or current evidence of alcohol abuse.\n\n          3. Scheduled to receive moderately or highly emetogenic antineoplastic agent in addition\n             to the AC regimen, from 6 hours after the start of the AC chemotherapy on Day 1 and up\n             to Day 1 of Cycle 2.\n\n          4. Received or is scheduled to receive radiation therapy to the abdomen or the pelvis\n             within 1 week prior to the start of AC chemotherapy administration on Day 1 or between\n             Days 1 to 5, inclusive.\n\n          5. Any vomiting, retching, or nausea (grade 1 as defined by National Cancer Institute)\n             within 24 hours prior to the start of AC chemotherapy administration on Day 1.\n\n          6. Symptomatic primary or metastatic central nervous system (CNS) malignancy.\n\n          7. Active peptic ulcer disease, gastrointestinal obstruction, increased intracranial\n             pressure, hypercalcemia, an active infection or any illness or medical conditions\n             (other than malignancy) that, in the opinion of the Investigator, may confound the\n             results of the study, represent another potential etiology for emesis and nausea\n             (other than chemotherapy-induced nausea and vomiting [CINV]) or pose unwarranted risks\n             in administering the study drugs to the patient.\n\n          8. Known hypersensitivity or contraindication to 5 hydroxytryptamine type 3 (5-HT3)\n             receptor antagonists (e.g., palonosetron, ondansetron, granisetron, dolasetron,\n             tropisetron, ramosetron), to dexamethasone, or to neurokinin-1 (NK1) receptor\n             antagonists (e.g., aprepitant, rolapitant).\n\n          9. Known contraindication to the IV administration of 50 mL 5% glucose solution.\n\n         10. Participation in a previous clinical trial involving IV fosnetupitant or oral\n             netupitant administered alone or in combination with palonosetron.\n\n         11. Any investigational drugs taken within 4 weeks prior to Day 1, and/or is scheduled to\n             receive any investigational drug (other than those planned by the study protocol)\n             during the present study.\n\n         12. Systemic corticosteroid therapy within 72 hours prior to the start of AC chemotherapy\n             administration on Day 1, except the dexamethasone provided as additional study drug.\n             However, topical and inhaled corticosteroids are permitted.\n\n         13. Scheduled to receive bone marrow transplantation and/or stem cell rescue therapy\n             during the study participation.\n\n         14. Other than as administered as part of the study protocol, any medication with known or\n             potential antiemetic activity within 24 hours prior to the start of AC chemotherapy\n             administration on Day 1, including:\n\n               -  5-HT3 receptor antagonists (e.g., ondansetron, granisetron, dolasetron,\n                  tropisetron, ramosetron, palonosetron)\n\n               -  NK1 receptor antagonists (e.g., aprepitant, fosaprepitant, rolapitant or any\n                  other new drug of this class)\n\n               -  benzamides (e.g., metoclopramide, alizapride)\n\n               -  phenothiazines (e.g., prochlorperazine, promethazine, fluphenazine, perphenazine,\n                  thiethylperazine, chlorpromazine)\n\n               -  benzodiazepines (except if the subject is receiving such medication for sleep or\n                  anxiety and has been on a stable dose for at least seven days prior to Day 1).\n\n               -  butyrophenones (e.g., haloperidol, droperidol)\n\n               -  anticholinergics (e.g., scopolamine, with the exception of inhaled\n                  anticholinergics for respiratory disorders, e.g., ipratropium bromide)\n\n               -  antihistamines (e.g., cyclizine, hydroxyzine, diphenhydramine, chlorpheniramine)\n\n               -  domperidone\n\n               -  mirtazapine\n\n               -  olanzapine\n\n               -  prescribed cannabinoids (e.g., tetrahydrocannabinol or nabilone)\n\n               -  Over The Counter (OTC) antiemetics, OTC cold or OTC allergy medications.\n\n         15. Scheduled to receive any strong or moderate inhibitor of CYP3A4 during the efficacy\n             assessment period (Day 1 to Day 5, inclusive) or its intake within 1 week prior to Day\n             1.\n\n         16. Scheduled to receive any CYP3A4 inducer during the efficacy assessment period (Day 1\n             to Day 5, inclusive) or its intake within 4 weeks prior to Day 1, with the exception\n             of corticosteroids (for which exclusion criterion #12 applies).\n\n         17. History or predisposition to cardiac conduction abnormalities, except for incomplete\n             right bundle branch block.\n\n         18. History of risk factors for Torsades de Pointes (heart failure, hypokalemia, family\n             history of Long QT Syndrome).\n\n         19. Severe or uncontrolled cardiovascular diseases, including myocardial infarction within\n             3 months prior to Day 1, unstable angina pectoris, significant valvular or pericardial\n             disease, history of ventricular tachycardia, symptomatic Congestive Heart Failure\n             (CHF) New York Heart Association (NYHA) class III-IV, and severe uncontrolled arterial\n             hypertension.\n\n        All exclusion criteria with the exception of criteria #5, #12, and #14 will be checked at\n        screening visit (Visit 1). Exclusion criteria #5, #12, and #14 will be checked at Day 1\n        (Visit 2) only.\n\n        Exclusion criteria #3, #4, #7, #11, #13, #15, and #16 need to be re-checked at Day 1 (Visit\n        2).\n\n        Cycles 2 to 4:\n\n        The following exclusion criteria must be checked prior to inclusion at each repeated cycle:\n\n          1. Scheduled to receive moderately or highly emetogenic antineoplastic agent in addition\n             to the AC regimen, from 6 hours after the start of the AC chemotherapy on Day 1 of\n             current cycle and up to Day 1 of the next cycle.\n\n          2. Active infection or uncontrolled disease that may pose unwarranted risks in\n             administering the study drugs to the patient.\n\n          3. Started any of the prohibited medications.\n\n          4. Any vomiting, retching, or nausea (grade ? 1 as defined by National Cancer Institute)\n             within 24 hours prior to the start of AC chemotherapy administration on Day 1.\n\n          5. Received or is scheduled to receive radiation therapy to the abdomen or the pelvis\n             within 1 week prior to the start of AC chemotherapy administration on Day 1 or between\n             Days 1 to 5.\n\n          6. Symptomatic primary or metastatic CNS malignancy.\n\n          7. Any illness or medical condition that, in the opinion of the investigator, may\n             confound the results of the study or pose unwarranted risks in administering the\n             investigational product or dexamethasone to the patient.\n\n        All exclusion criteria, with exception of criterion #4, will be checked at screening visit\n        (Visit 1). Exclusion criterion #4 will be checked at Day 1 (Visit 2) only. Exclusion\n        criteria #2, #3 and #5 need to be re-checked at Day 1 (Visit 2).Xx_NEWLINE_xXBetween day +60 and day +90 after allogeneic HCTXx_NEWLINE_xXSmokes >= 1 cigarettes per day (cpd)Xx_NEWLINE_xXHas a condition or psychological difficulties that affects day-to-day activitiesXx_NEWLINE_xXWomen who are premenopausal, are on a stable contraceptive regimen, and are planning to continue the same regimen through surgery are eligible to participate; for women who are on hormonal contraception regimens that have a placebo phase, the following should be recorded regarding the day of baseline core biopsy and the day of surgery: the agent, whether they are in active or placebo phase, the day of the phase (e.g. day 13 of 21-day active phase or day 4 of 7-day placebo phase); this information will have to be back-calculated for the day of core biopsy, but best attempt should be madeXx_NEWLINE_xXWomen who are using postmenopausal hormones, and are planning to continue the same regimen through surgery are eligible to participate; if the hormone therapy regimen is cyclical, the following should be recorded regarding the day of baseline core biopsy and day of surgery: the agent, the day of the phase (e.g. day 13 of 14-day estrogen phase etc); this information will have to be back-calculated for the day of core biopsy, but best attempt should be madeXx_NEWLINE_xXRPFNA performed within 6 months of the study entry visit and in the follicular portion (day 1-10) of the menstrual cycle; note that day 1 is defined as the first day of bleeding; for non-menstruating women, RPFNA during the follicular phase must be confirmed by hormone levels drawn on the day of RPFNA; either clinical laboratory results are sent to protocol chair for assessment of menstrual cycle phase; or an additional frozen serum aliquot is sent to University of Kansas Medical Center (KUMC) for assay of hormone levels and phase confirmation; confirmation of follicular phase will be included in the eligibility report for the potential subjectXx_NEWLINE_xXhaving demonstrated inability to tolerate treatment with an injectable hypomethylating agent because of unacceptable drug-related toxicity after at least 3 months of attempted treatment: Three 28-day cycles of azacitidine for injection or decitabine 5-day regimen; two 42-day cycles of decitabine 3-day regimen.Xx_NEWLINE_xXKnown clinically-significant doubling in marrow or perIP (INVESTIGATIONAL PRODUCT) heral blood blast percentage (to ? 20%) in the 8-week period leading to the first dose of IP (INVESTIGATIONAL PRODUCT) (Cycle 1, Day 1)Xx_NEWLINE_xX?100% increase in WBC count (myeloid cell line and monocyte series) within the 8-week period leading to Cycle 1, Day 1Xx_NEWLINE_xXLast anticancer treatment (chemotherapy, IMiD, PI, molecular targeted therapy) < 2 weeks prior to study day 1 or treatment with a therapeutic antibody less than 4 weeks prior to study day 1 as well as systemic radiation therapy within 28 days prior to study day 1 or focal radiotherapy within 14 days prior to study day 1.Xx_NEWLINE_xXPatient must start everolimus 10mg plus exemestane 25mg treatment on Cycle 1 Day 1 of trialXx_NEWLINE_xXWashout period prior to Day 1 Cycle 1:Xx_NEWLINE_xXPatients must have had treatment with temozolomide, lomustine (CCNU) or PCV (procarbazine, lomustine [CCNU], vincristine) chemotherapy prior to histopathologic transformation to glioblastoma or prior to identification of one of the genetic alterations specified; notes or records from the treating oncologist are required for documentation of treatment history; prior treatment with at least one of the following chemotherapy schedules is required to be eligible:\r\n* At least one 6 week course of continuous daily temozolomide\r\n* At least six 28-day cycles given in one of the following schedules:\r\n** Daily for 5 days of a 28-day cycle\r\n** Daily for 21 days of a 28-day cycle\r\n** Daily for 14 days of a 28-day cycle\r\n** Alternating 7 days on/7 days per 28-day cycle\r\n** Continuous daily dosing of a 28-day cycle\r\n* Other schedules of temozolomide may be considered after discussion with the overall principal investigator\r\n* At least 3 cycles of PCV or lomustine (CCNU) chemotherapyXx_NEWLINE_xXExperimental therapy within 4 weeks prior to first dose of study drug treatment in Cycle 1Xx_NEWLINE_xXMalignancies other than urothelial carcinoma within 5 years prior to Cycle 1, Day 1Xx_NEWLINE_xXUse of any other experimental medication(s) within 14 days or 5 half-lives, but in no case <14 days prior to the start of treatment on Cycle 1, Day 1, except if approved by the Sponsor.Xx_NEWLINE_xX